How Johnson & Johnson’s Infectious Diseases Portfolio Perform in 2017

In 4Q17, Johnson & Johnson’s (JNJ) Infectious Diseases segment generated revenues of $800.0 million, which is ~5.1% growth on a year-over-year (or YoY) basis. In 4Q17, in the US market and international markets, JNJ’s Infectious Diseases segment generated revenues of $338.0 million and $462.0 million, respectively, compared to $354.0 million and $407.0 million in 4Q16.

In fiscal 2017, JNJ’s Infectious Diseases segment generated revenues of ~$3.2 billion, which is an ~2% decline on a YoY basis. In 2017, JNJ’s Infectious Diseases segment generated revenues of $1.4 billion and $1.8 billion, respectively, in the US market and international markets.

In 4Q17, Edurant reported revenues of $192.0 million, which reflected ~16.4% growth on a YoY basis. In 4Q17, Edurant generated revenues of $14.0 million and $178.0 million, respectively, in the US market and international markets.

In fiscal 2017, Edurant reported revenues of $714.0 million, which is ~25.0% growth on a YoY basis. In the US market and international markets, Edurant reported fiscal 2017 revenues of $58.0 million and $656.0 million, respectively, which reflected ~11.5% and ~25.9% growth on a YoY basis. Edurant is used for the treatment of HIV-1 infection.

In 4Q17, JNJ’s Prezista/Prezcobix/Rezolsta/Symtuza together generated revenues of $470.0 million, which is ~5.1% growth on a YoY basis and 1.0% growth on a quarter-over-quarter basis. In 4Q17, Prezista/Prezcobix/Rezolsta/Symtuza generated revenues of $285.0 million and $185.0 million, respectively, in the US market and international markets.

In fiscal 2017, Prezista/Prezcobix/Rezolsta/Symtuza generated revenues of $1.8 billion, which reflected an ~2.0% YoY decline. In 2017, in the US and international markets, Prezista/Prezcobix/Rezolsta/Symtuza generated revenues of $1.1 billion and $712.0 million, respectively, compared to $1.1 billion and $708.0 million. Prezista is used in the treatment of HIV-1 infection.

The launch of Symtuza, consistent growth of Prezcobix and Rezolsta, and strong uptake of Edurant primarily attributed to the revenue growth of JNJ’s Infectious Disease segment in 4Q17.

Johnson & Johnson’s HIV drugs compete with Lexiva, an HIV drug from Pfizer and GlaxoSmithKline’s (GSK) joint venture ViiV Healthcare; Bristol-Myers Squibb’s (BMY) Reyataz and Sustiva; and Gilead Sciences’ (GILD) Genvoya and Odefsey.